Salamanca

• A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
  2025-521975-30-00 4 2025-10-03 Newly Diagnosed Multiple Myeloma
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutec … Recruiting
  2024-518015-19-00 4 2025-09-24 Colorectal Cancer
• Trial of an investigational drug after the rejection of an allogeneic transplant. Recruiting
  2022-503063-15-00 7 2025-09-22 Multiple myeloma.
• A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing … Recruiting
  2024-512752-38-00 5 2025-09-09 Adjunctive and maintenance treatment to HCT
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
• A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting
  2025-521152-34-00 4 2025-09-04 mantle cell lymphoma (MCL)
• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 4 2025-08-29 colorectal cancer
• A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting
  2024-519928-24-00 4 2025-08-21 Myelodysplastic Syndrome
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with Immune Thrombocytopenia Recruiting
  2024-520359-26-00 4 2025-08-20 Immune Thrombocytopenia (ITP)
• A clinical trial for patients with relapsed or refractory multiple myeloma, using an experimental drug called ISB 2001 for the first time in … Recruiting
  2023-507071-21-01 1 2025-08-14 Relapsed/Refractory Multiple Myeloma
• SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting
  2024-512132-29-00 4 2025-08-06 Metastatic castration-resistant prostate cancer
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting
  2024-515098-93-00 5 2025-07-22 Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 4 2025-07-02 Non-small cell lung cancer (NSCLC)
• Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME … Recruiting
  2024-512696-12-00 4 2025-06-24 BCR-ABL1+ Chronic Myeloid Leukemia
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting
  2024-517812-31-00 6 2025-05-21 Haemophilia A
• Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or … Recruiting
  2024-514531-18-00 3 2025-05-20 Acute Myeloid Leukemias
• Cetuximab With or Without Paclitaxel After Pembrolizumab-Chemotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. Recruiting
  2024-514953-31-00 4 2025-05-20 Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva … Recruiting
  2024-515984-68-00 4 2025-05-20 Non-small cell lung cancer (NSCLC)
• A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting
  2023-506260-14-00 4 2025-05-13 multiple myeloma
• A study with three treatments for higher-risk chronic myelomonocytic leukaemia. Recruiting
  2024-511102-22-00 4 2025-05-13 chronic myelomonocytic Leukemia

Showing 97–120 of 470 trials